Skip to main content
Home

Main navigation

  • Home
  • About pCPA
    • Who We Are
    • Governance
    • Strategic Plan
    • pCPA Revitalization
    • FAQs
  • Negotiations
    • Recent Updates
    • Forms and Publications
    • Brand Name Drugs
      • Negotiations Status
      • Negotiation Process
    • Generic Drugs
    • Biologics/Biosimilars
  • Contact Us
  • EN
  • FR

Forms and Publications

  • pCPA Brand Process Guidelines
  • pCPA Brand Process FAQs

 

  • First Principles for Subsequent Entry Biologics
  • Biologics Policy Directions & pCPA Negotiations
  • Biologics Policy Directions & pCPA Negotiations FAQs
  • Biosimilars Review Process & pCPA Negotiations Update
  • National Online Consultation on the Use and Implementation of Biosimilars
  • National In Person Consultation on the Use and Implementation of Biosimilars 
  • Manufacturer Notification of Intent to Negotiate a Biosimilar form

 

  • TPF/Market Entry Form
  • TPF/Market Exit Form
  • Pan-Canadian Price Tier Confirmation Process Flowchart
  • Pan-Canadian Price Tier Market Exit Eligibility Flowchart
  • Generics Tiered Pricing Framework FAQs
  • Historical Products Policy 

 

  • pCPA Dashboard

 

  • pCPA Strategic Plan 
  • pCPA Strategic Revitalization Summary
  • IBM Report Pan Canadian Drugs Negotiations Report
    • Appendices 3-6 March 2014
About pCPA
  • Who We Are
  • Governance
  • Strategic Plan
  • FAQs
Negotiations
  • Recent Updates
  • Forms and Publications
  • Brand Name Drug Negotiations Status
  • Negotiation Process
  • Generic Drugs
  • Biologics/Biosimilars

601 – 1075 Bay St
Toronto, ON, M5S 2B1

416-326-3368

[email protected]

 

footer pcpa logo

© Queen’s Printer for Ontario, 2012–2023

Privacy Policy   Terms of Use